ERASCA INC's ticker is and the CUSIP is 29479A108. A total of 118 filers reported holding ERASCA INC in Q1 2023. The put-call ratio across all filers is 4.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,750 | +159.6% | 7,995 | +263.7% | 0.00% | – |
| Q2 2023 | $6,066 | +108.6% | 2,198 | +127.5% | 0.00% | – |
| Q1 2023 | $2,908 | -100.0% | 966 | -100.0% | 0.00% | -100.0% |
| Q4 2022 | $40,674,521 | -71.5% | 9,437,244 | -48.5% | 0.00% | -73.3% |
| Q3 2022 | $142,912,000 | +40.4% | 18,322,047 | +0.2% | 0.02% | +50.0% |
| Q2 2022 | $101,812,000 | -33.5% | 18,278,655 | +2.6% | 0.01% | -16.7% |
| Q1 2022 | $153,170,000 | -24.5% | 17,810,513 | +36.8% | 0.01% | -20.0% |
| Q4 2021 | $202,882,000 | +20.4% | 13,021,950 | +64.0% | 0.02% | +15.4% |
| Q3 2021 | $168,531,000 | – | 7,942,023 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 11,055,554 | $21,779,441 | 14.15% |
| EDBI Pte Ltd | 888,888 | $1,751,109 | 1.90% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 1,926,000 | $3,794,220 | 1.28% |
| Cormorant Asset Management, LP | 10,813,246 | $21,302,095 | 1.24% |
| AH Equity Partners LSV II, L.L.C. | 312,500 | $615,625 | 0.64% |
| Artal Group S.A. | 4,721,194 | $9,301 | 0.40% |
| PFM Health Sciences, LP | 3,930,633 | $7,743,347 | 0.36% |
| ARMISTICE CAPITAL, LLC | 8,356,000 | $16,461,320 | 0.25% |
| SANDERS MORRIS HARRIS LLC | 425,297 | $816,569 | 0.17% |
| Prosight Management, LP | 264,710 | $521,479 | 0.16% |